Contraception in Medically Complex Adolescents and Young Adults

References

• Scott N, Maslyanskaya S. Contraceptive needs of adolescents with chronic illness. Pediatr Ann. 2019;48(2):e78–e85. doi:10.3928/19382359-20190121-01
   PubMed Web of Science ®Google Scholar
• Sawyer SM, Drew S, Yeo MS, Britto MT. Adolescents with a chronic condition: challenges living, challenges treating. Lancet. 2007;369(9571):1481–1489. doi:10.1016/S0140-6736(07)60370-5
   PubMed Web of Science ®Google Scholar
• Surís JC, Michaud PA, Akre C, Sawyer SM. Health risk behaviors in adolescents with chronic conditions. Pediatrics. 2008;122(5). doi:10.1542/PEDS.2008-1479
   PubMed Web of Science ®Google Scholar
• Marcell AV, Burstein GR, Braverman P. Sexual and reproductive health care services in the pediatric setting. Pediatrics. 2017;140(5). doi:10.1542/PEDS.2017-2858/37895
   PubMed Web of Science ®Google Scholar
• World Health Organization. Reproductive Health and Research, World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. 2015:268.
   Google Scholar
• Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recommendations Rep. 2020;65(3):1–104. doi:10.15585/MMWR.RR6503A1
   Google Scholar
• Standards & guidance - faculty of sexual and reproductive healthcare. Available from: https://www.fsrh.org/standards-and-guidance/. Accessed August 21, 2023.
   Google Scholar
• Billow JA. Choosing condoms. Am Pharm. 1992;NS32(9):55–58. doi:10.1016/S0160-3450(15)31005-9
   PubMedGoogle Scholar
• Thomas MA, Chappell BT, Maximos B, Culwell KR, Dart C, Howard B. A novel vaginal pH regulator: results from the Phase 3 AMPOWER contraception clinical trial. Contracept X. 2020;2:100031. doi:10.1016/J.CONX.2020.100031
   PubMedGoogle Scholar
• Cooper DB, Patel P, Mahdy H Oral Contraceptive Pills. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 28613632.
   Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 2010;81(6):474–480. doi:10.1016/J.CONTRACEPTION.2010.01.016
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstetrics Gynecol. 2010;116(2 Pt 1):275–283. doi:10.1097/AOG.0B013E3181E79440
   PubMed Web of Science ®Google Scholar
• Benefits and Risks. Available from: https://www.xulane.com/en/meet-xulane/benefits-and-risks. Accessed August 13, 2023.
   Google Scholar
• Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®). Int J Womens Health. 2010;2(1):401. doi:10.2147/IJWH.S6162
   PubMedGoogle Scholar
• Micks EA, Jensen JT. A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year. Expert Opin Drug Deliv. 2020;17(6):743–752. doi:10.1080/17425247.2020.1764529
   PubMed Web of Science ®Google Scholar
• Gallo MF, Grimes DA, Lopez LM, Schulz KF, D’Arcangues C. Combination injectable contraceptives for contraception. Cochrane Database Syst Rev. 2008;2008(4). doi:10.1002/14651858.CD004568.PUB3
   PubMedGoogle Scholar
• Schreiber CA, Barnhart K. Chapter 36 - contraception. In: Strauss JF, Barbieri RL, editors. Yen and Jaffe’s Reproductive Endocrinology (Eighth Edition). 2019:962–978.e4. https://www.sciencedirect.com/science/article/pii/B9780323479127000366. Accessed August 14, 2023.
   Google Scholar
• Baker CC, Chen MJ. New contraception update — annovera, Phexxi, Slynd, and Twirla. Curr Obstet Gynecol Rep. 2022;11(1):21. doi:10.1007/S13669-021-00321-4
   PubMed Web of Science ®Google Scholar
• Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95(11):4909–4916. doi:10.1210/JC.2010-0032
   PubMed Web of Science ®Google Scholar
• Ali M, Akin A, Bahamondes L, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31(11):2491. doi:10.1093/HUMREP/DEW222
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, McQuillan SK. What do I need to know about the etonogestrel-relesasing contraceptive implant (Nexplanon)? Paediatr Child Health. 2021;26(7):394. doi:10.1093/PCH/PXAB014
   PubMed Web of Science ®Google Scholar
• Moray KV, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health. 2021;18(1):4. doi:10.1186/S12978-020-01054-Y
   PubMed Web of Science ®Google Scholar
• Lanzola EL, Ketvertis K. Intrauterine device. StatPearls; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557403/. Accessed August 18, 2023.
   Google Scholar
• Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med. 2021;384(4):335–344. doi:10.1056/NEJMOA2022141/SUPPL_FILE/NEJMOA2022141_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Sexually transmitted disease surveillance; 2019. Available from: https://www.cdc.gov/std/statistics/2019/default.htm. Accessed March 13, 2022.
   Google Scholar
• Adolescents with HIV experience high rates of unintended pregnancies…. Available from: https://www.reliasmedia.com/articles/148044-adolescents-with-hiv-experience-high-rates-of-unintended-pregnancies. Accessed March 16, 2023.
   Google Scholar
• Patel RC, Bukusi EA, Baeten JM. Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother. 2018;19(1):1–12. doi:10.1080/14656566.2017.1378345
   PubMed Web of Science ®Google Scholar
• Grimes DA, Lopez LM, Raymond EG, Halpern V, Nanda K, Schulz KF. Spermicide used alone for contraception. Cochrane Database Syst Rev. 2013;2013(9). doi:10.1002/14651858.CD005218.PUB3
   Google Scholar
• Haddad LB, Polis CB, Sheth AN, et al. Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep. 2014;11(4):447. doi:10.1007/S11904-014-0236-6
   PubMed Web of Science ®Google Scholar
• HIV Information | the Well Project. Available from: https://www.thewellproject.org/hiv-information/birth-control-and-hivhttps://sti.bmj.com/content/80/3/167. Accessed March 16, 2023..
   Google Scholar
• Tasker C, Davidow A, Roche NE, Chang TL. Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection. Immunohorizons. 2017;1(9):223–235. doi:10.4049/immunohorizons.1700047
   PubMedGoogle Scholar
• Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31(1):79–97. doi:10.1210/er.2009-0018
   PubMed Web of Science ®Google Scholar
• Ahmed K, Baeten JM, Beksinska M, et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–313. doi:10.1016/S0140-6736(19)31288-7
   PubMed Web of Science ®Google Scholar
• Marcus JL, Snowden JM, Murray Horwitz ME, et al. Use of intrauterine devices and risk of human immunodeficiency virus acquisition among insured women in the United States. Clin Infect Dis. 2020;70(10):2221. doi:10.1093/CID/CIZ791
   PubMed Web of Science ®Google Scholar
• Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16(2):149–156. doi:10.3851/IMP1725
   PubMed Web of Science ®Google Scholar
• Landolt NK, Phanuphak N, Ubolyam S, et al. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. J Acquir Immune Defic Syndr. 2014;66(2):e50–e52. doi:10.1097/QAI.0000000000000134
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Darin KM, Nakalema S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clinl Infect Dis. 2016;62(6):675–682. doi:10.1093/CID/CIV1001
   PubMed Web of Science ®Google Scholar
• Perry SH, Swamy P, Preidis GA, Mwanyumba A, Motsa N, Sarero HN. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS. 2014;28(5):791–793. doi:10.1097/QAD.0000000000000177
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb - Bristol-Myers Squibb submits new drug application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1. Available from: https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Submits-New-Drug-Application-to-US-FDA-for-a-Fixed-Dose-Combination-Tablet-of-Atazanavir-Sulfate-with-Cobicistat-for-People-Living-with-HIV-1/default.aspx. Accessed March 16, 2023.
   Google Scholar
• Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive Efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1–infected women: pharmacokinetic results of ACTG Trial A5188. J Acquir Immune Defic Syndr. 2010;55(4):473. doi:10.1097/QAI.0B013E3181EB5FF5
   PubMed Web of Science ®Google Scholar
• Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011;16(2):157–164. doi:10.3851/IMP1724
   PubMed Web of Science ®Google Scholar
• Sekar V, Lavreys L, Van De Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54(10):4440–4445. doi:10.1128/AAC.01749-09
   PubMed Web of Science ®Google Scholar
• Perkins RB, Guido RL, Saraiya M, et al. Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016–2020. J Womens Health. 2021;30(1):5. doi:10.1089/JWH.2020.8918
   Web of Science ®Google Scholar
• Gawron LM. Contraceptive use in women with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018;14(3):176–179.
   PubMedGoogle Scholar
• Brosens I, Benagiano G. Pregnancy and reproductive health after solid organ transplantation. Best Pract Res Clin Obstet Gynaecol. 2014;28(8):1113. doi:10.1016/j.bpobgyn.2014.08.002
   PubMed Web of Science ®Google Scholar
• Martin J, Kane SV, Feagins LA. Fertility and contraception in women with inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:1.
   Google Scholar
• Lim SM, Nam CM, Kim YN, et al. The effect of the menstrual cycle on inflammatory bowel disease: a prospective study. Gut Liver. 2013;7(1):51–57. doi:10.5009/GNL.2013.7.1.51
   PubMed Web of Science ®Google Scholar
• Rolston VS, Boroujerdi L, Long MD, et al. The influence of hormonal fluctuation on inflammatory bowel disease symptom severity - a Cross-Sectional Cohort Study. Inflamm Bowel Dis. 2018;24(2):387–393. doi:10.1093/ibd/izx004
   PubMed Web of Science ®Google Scholar
• Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62(8):1153–1159. doi:10.1136/gutjnl-2012-302362
   PubMed Web of Science ®Google Scholar
• a ORLSY, b NET, a JMMBMMNDL, Jamal MM, Bechtold MM, Nguyen DL. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 2017;29(9):1064–1070. doi:10.1097/MEG.0000000000000915
   PubMed Web of Science ®Google Scholar
• Emans SJ, Laufer MR. Emans, Laufer, Goldstein’s pediatric and adolescent gynecology; 2011:603. Available from: https://shop.lww.com/Emans--Laufer--Goldstein-s-Pediatric-and-Adolescent-Gynecology/p/9781975107444. Accessed March 29, 2023.
   Google Scholar
• Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus; 2005. Available from: www.nejm.org. Accessed March 2, 2024.
   Google Scholar
• Pasvol TJ, Bloom S, Segal AW, Rait G, Horsfall L. Use of contraceptives and risk of inflammatory bowel disease: a nested case–control study. Aliment Pharmacol Ther. 2022;55(3):318–326. doi:10.1111/apt.16647
   PubMed Web of Science ®Google Scholar
• Brady PC, Missmer SA, Laufer MR. Hepatic adenomas in adolescents and young women with endometriosis treated with norethindrone acetate. J Pediatr Adolesc Gynecol. 2017;30(3):422–424. doi:10.1016/J.JPAG.2016.12.002
   PubMed Web of Science ®Google Scholar
• Jin HY, Lim JS, Lee Y, et al. Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease. BMC Pediatr. 2021;21(1). doi:10.1186/s12887-021-02496-4
   Web of Science ®Google Scholar
• OPTN metrics. Available from: https://insights.unos.org/OPTN-metrics/. Accessed March 26, 2023.
   Google Scholar
• Parolin MB, Rabinovitch I, Urbanetz AA, Scheidemantel C, Cat ML, Coelho JCU. Impact of successful liver transplantation on reproductive function and sexuality in women with advanced liver disease. Transplant Proc. 2004;36(4):943–944. doi:10.1016/j.transproceed.2004.03.124
   PubMed Web of Science ®Google Scholar
• Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007;14(2):119–125. doi:10.1053/j.ackd.2007.01.002
   PubMed Web of Science ®Google Scholar
• Szymusik I, Szpotanska-Sikorska M, Mazanowska N, Ciszek M, Wielgos M, Pietrzak B. Contraception in women after organ transplantation. Transplant Proc. 2014;46(10):3268–3272. doi:10.1016/j.transproceed.2014.09.104
   PubMed Web of Science ®Google Scholar
• Mattix Kramer HJ, Tolkoff-Rubin NE, Williams WW, Cosimi AB, Pascual MA. Reproductive and contraceptive characteristics of premenopausal kidney transplant recipients. Prog Transplant. 2003;13(3):193–196. doi:10.1177/152692480301300305
   PubMedGoogle Scholar
• Muehrer RJ, Lanuza DM, Brown RL, Djamali A. Sexual concerns among kidney transplant recipients. Clin Transplant. 2014;28(11):1294–1302. doi:10.1111/ctr.12454
   PubMed Web of Science ®Google Scholar
• Hendren EM, Reynolds ML, Mariani LH, et al. Confidence in women’s health: a cross border survey of adult nephrologists. J Clin Med. 2019;8(2):176. doi:10.3390/jcm8020176
   PubMed Web of Science ®Google Scholar
• Ritchie J, Seidman D, Srisengfa Y, Perito ER, Sarkar M. Family planning in liver transplant: patient and provider knowledge and practices. Liver Transpl. 2020;26(10):1233–1240. doi:10.1002/lt.25835
   PubMed Web of Science ®Google Scholar
• Andreoni KA, Forbes R, Andreoni RM, Phillips G, Stewart H, Ferris M. Age-related kidney transplant outcomes: health disparities amplified in adolescence. JAMA Intern Med. 2013;173(16):1524–1532. doi:10.1001/jamainternmed.2013.8495
   PubMed Web of Science ®Google Scholar
• Van Arendonk KJ, Boyarsky BJ, Orandi BJ, et al. National trends over 25 years in pediatric kidney transplant outcomes. Pediatrics. 2014;133(4):594–601. doi:10.1542/peds.2013-2775
   PubMed Web of Science ®Google Scholar
• Pankhurst T, Evison F, Mytton J, Williamson S, Kerecuk L, Lipkin G. Young adults have worse kidney transplant outcomes than other age groups. Nephrol Dial Transplant. 2020;35(6):1043–1051. doi:10.1093/ndt/gfaa059
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Lamb KE, Zheng J, Schechtman KB, Meier-Kriesche HU. Across all solid organs, adolescent age recipients have worse transplant organ survival than younger age children: a US national registry analysis. Pediatr Transplant. 2015;19(5):471–476. doi:10.1111/petr.12464
   PubMed Web of Science ®Google Scholar
• Kaboré R, Couchoud C, Macher MA, et al. Age-dependent risk of graft failure in young kidney transplant recipients. Transplantation. 2017;101(6):1327–1335. doi:10.1097/TP.0000000000001372
   PubMed Web of Science ®Google Scholar
• Ritchie AG, Clayton PA, McDonald SP, Kennedy SE. Age-specific risk of renal graft loss from late acute rejection or non-compliance in the adolescent and young adult period. Nephrology (Carlton). 2018;23(6):585–591. doi:10.1111/nep.13067
   PubMed Web of Science ®Google Scholar
• Van Arendonk KJ, James NT, Boyarsky BJ, et al. Age at graft loss after pediatric kidney transplantation: exploring the high-risk age window. Clin J Am Soc Nephrol. 2013;8(6):1019–1026. doi:10.2215/CJN.10311012
   PubMed Web of Science ®Google Scholar
• Rose C, Gill J, Zalunardo N, Johnston O, Mehrotra A, Gill JS. Timing of pregnancy after kidney transplantation and risk of allograft failure. Am J Transplant. 2016;16(8):2360–2367. doi:10.1111/ajt.13773
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–596. doi:10.1002/ajmg.a.35223
   PubMed Web of Science ®Google Scholar
• Moritz MJ, Constantinescu S, Coscia LA, Armenti D. Mycophenolate and pregnancy: teratology principles and national transplantation pregnancy registry experience. Am J Transplant. 2017;17(2):581–582. doi:10.1111/ajt.14085
   PubMed Web of Science ®Google Scholar
• Paziana K, Del monaco M, Cardonick E, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279–294. doi:10.1007/s40264-013-0034-x
   PubMed Web of Science ®Google Scholar
• Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res a Clin Mol Teratol. 2009;85(7):647–654. doi:10.1002/bdra.20583
   PubMed Web of Science ®Google Scholar
• Josephson MA, McKay DB. Women and transplantation: fertility, sexuality, pregnancy, contraception. Adv Chronic Kidney Dis. 2013;20(5):433–440. doi:10.1053/j.ackd.2013.06.005
   PubMed Web of Science ®Google Scholar
• Kusumi K, Shaikhkhalil A, Patel HP, Mahan JD. Promoting bone health in children and adolescents following solid organ transplantation. Pediatr Transplant. 2021;25(1). doi:10.1111/PETR.13940
   PubMed Web of Science ®Google Scholar
• Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception. 2021;104(5):556–560. doi:10.1016/j.contraception.2021.06.007
   PubMed Web of Science ®Google Scholar
• Juliato CRT, Stahlschmidt P, Fernandes A, Monteiro I, Bahamondes L. A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant. Contraception. 2018;98(3):252–254. doi:10.1016/j.contraception.2018.04.017
   PubMed Web of Science ®Google Scholar
• Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series. Contraception. 2017;95(4):378–381. doi:10.1016/j.contraception.2016.11.008
   PubMed Web of Science ®Google Scholar